neutralizing antibody - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 1.71 [0.56, 5.21]< 10%1 study (1/-)17.4 %lownot evaluable highcrucial-
clinical improvement 0.85 [0.56, 1.29]> 10%1 study (1/-)22.3 %lownot evaluable highimportant-
clinical improvement (7-day) 0.85 [0.56, 1.29]> 10%1 study (1/-)22.3 %lownot evaluable highimportant-
hospital discharge 0.97 [0.78, 1.20]> 10%1 study (1/-)39.1 %lownot evaluable highimportant-
time to recovery 1.06 [0.77, 1.46]> 10%1 study (1/-)63.8 %lownot evaluable highnon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.